fair enough view, been a tough few years for biotech, but not sure why someone didn't swoop on a few in 2023 including Cynata. Valuation under $20m
Not sure anyone would be interested in 50c now, I am sure the top holders are not.
I am more interested in a big name partnering an indication.
Near term GvHD looks best after P2
I am also not sure why the Japanese haven't picked up an indication yet.
Ann: CYP Presents at Major International Cell Therapy Conference, page-12
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $39.74M | |||
| Open | High | Low | Value | Volume |
| 22.0¢ | 22.5¢ | 22.0¢ | $29.06K | 131.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 951 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.0¢ | 10000 | 1 |
View Market Depth
| Last trade - 15.59pm 08/11/2024 (20 minute delay) ? |
| CYP (ASX) Chart |